

Pfenex to Present at 13th Annual BIO Investor Forum

- BIO Investor Forum to be held October 7-8 in San Francisco -

SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today announced that it will be presenting at the 13th Annual BIO Investor Forum in San Francisco at the Palace Hotel. Paul Wagner, chief financial officer of Pfenex, will provide an overview of the company's development programs and business strategy on October 8, 2014 at 8:30 a.m. PDT. A live audio webcast and archive of the presentation will be available in the Investor Relations section of the Pfenex website at www.pfenex.com.

Pfenex has used, and intends to continue to use, its Investor Relations website (<http://pfenex.investorroom.com>), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (<http://pfenex.investorroom.com>).

About Pfenex Inc.

Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfenex Expression Technology[®] platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. For additional information please visit the Pfenex website at www.pfenex.com.

About the BIO Investor Forum

The 13th Annual [BIO Investor Forum](#) is an international investor conference focused on private and emerging public biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.

Logo - <http://photos.prnewswire.com/prnh/20140715/127348>

SOURCE Pfenex Inc.

For further information: Company Contact: Paul Wagner, Ph.D., Chief Financial Officer, (858) 352-4333, pwagner@pfenex.com; Investor Relations Contact: Westwicke Partners, LLC, Robert H. Uhl, Managing Director, (858) 356-5932, robert.uhl@westwicke.com

Additional assets available online:  [Photos \(1\)](#)